Literature DB >> 28667059

Hypercholesterolaemia and vascular dementia.

Jason P Appleton1, Polly Scutt1, Nikola Sprigg1, Philip M Bath2.   

Abstract

Vascular dementia (VaD) is the second commonest cause of dementia. Stroke is the leading cause of disability in adults in developed countries, the second major cause of dementia and the third commonest cause of death. Traditional vascular risk factors-diabetes, hypercholesterolaemia, hypertension and smoking-are implicated as risk factors for VaD. The associations between cholesterol and small vessel disease (SVD), stroke, cognitive impairment and subsequent dementia are complex and as yet not fully understood. Similarly, the effects of lipids and lipid-lowering therapy on preventing or treating dementia remain unclear; the few trials that have assessed lipid-lowering therapy for preventing (two trials) or treating (four trials) dementia found no evidence to support the use of lipid-lowering therapy for these indications. It is appropriate to treat those patients with vascular risk factors that meet criteria for lipid-lowering therapy for the primary and secondary prevention of cardiovascular and cerebrovascular events, and in line with current guidelines. Managing the individual patient in a holistic manner according to his or her own vascular risk profile is recommended. Although the paucity of randomized controlled evidence makes for challenging clinical decision making, it provides multiple opportunities for on-going and future research, as discussed here.
© 2017 The Author(s).

Entities:  

Keywords:  cholesterol; cognitive impairment; hypercholesterolaemia; statins; vascular dementia

Mesh:

Substances:

Year:  2017        PMID: 28667059     DOI: 10.1042/CS20160382

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  33 in total

1.  ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Authors:  Yashashwi Pokharel; Farah Mouhanna; Vijay Nambi; Salim S Virani; Ron Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca F Gottesman; Christie M Ballantyne; Melinda C Power
Journal:  Neurology       Date:  2019-05-01       Impact factor: 9.910

2.  Cerebroprotein Hydrolysate-I Inhibits Hippocampal Neuronal Apoptosis by Activating PI3K/Akt Signaling Pathway in Vascular Dementia Mice.

Authors:  Xiaolin Wu; Yingjuan Liu; Lin Zhu; Yue Wang; Yuqian Ren; Baohe Cheng; Leiming Ren; Keli Ge; Hongyun Li
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-17       Impact factor: 2.570

3.  Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOEɛ4 Status.

Authors:  Jagan A Pillai; Lei Kou; James Bena; Lisa Penn; James B Leverenz
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 4.  A Mini-Review of the NADPH oxidases in Vascular Dementia: Correlation with NOXs and Risk Factors for VaD.

Authors:  Dong-Hee Choi; Jongmin Lee
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

Review 5.  The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms.

Authors:  Bob G Schultz; Denise K Patten; Daniel J Berlau
Journal:  Transl Neurodegener       Date:  2018-02-27       Impact factor: 8.014

Review 6.  Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.

Authors:  Ramón Cacabelos; Arun Meyyazhagan; Juan C Carril; Pablo Cacabelos; Óscar Teijido
Journal:  J Pers Med       Date:  2018-01-03

Review 7.  The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.

Authors:  Michał Kosowski; Joanna Smolarczyk-Kosowska; Marcin Hachuła; Mateusz Maligłówka; Marcin Basiak; Grzegorz Machnik; Robert Pudlo; Bogusław Okopień
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

Review 8.  Effects of Plasma Lipids and Statins on Cognitive Function.

Authors:  Rui Li; Tian-Jun Wang; Pei-Yuan Lyu; Yang Liu; Wei-Hong Chen; Ming-Yue Fan; Jing Xu
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

9.  The effect of different combinations of vascular, dependency and cognitive endpoints on the sample size required to detect a treatment effect in trials of treatments to improve outcome after lacunar and non-lacunar ischaemic stroke.

Authors:  Stephen Dj Makin; Fergus N Doubal; Terence J Quinn; Philip Mw Bath; Martin S Dennis; Joanna M Wardlaw
Journal:  Eur Stroke J       Date:  2017-09-05

10.  Predictors of dementia after first ischemic stroke.

Authors:  Wafik Mahmoud El-Sheik; Aktham Ismail El-Emam; Ahmed Abd El-Galil Abd El-Rahman; Gelan Mahmoud Salim
Journal:  Dement Neuropsychol       Date:  2021 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.